Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STRIDE-CAP pilot observational test-negative design feasibility study
NL-OMON57861Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2025
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Trial of pneumococcal 21-valent conjugate vaccine, sponsored by Merck & Co. Started Apr 2025; status: completed.
02
Drugs
pneumococcal 21-valent conjugate vaccine
Beyond the preview
Go deeper on NL-OMON57861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON57861.